GLUT1 deficiency in cardiomyocytes does not accelerate the transition from compensated hypertrophy to heart failure

Renata O Pereira1, Adam R Wende2, Curtis Olsen2

  • 1Division of Endocrinology, Metabolism and Diabetes, and Program in Molecular Medicine, University of Utah School of Medicine, Salt Lake City, UT, 84112, USA; Fraternal Order of Eagles Diabetes Research Center and Division of Endocrinology and Metabolism, Carver College of Medicine, University of Iowa, Iowa City, IA, 52242, USA.

Insights

Glucose transporter type 1 (GLUT1) deficiency in heart muscle alters fuel use but does not worsen heart dysfunction or failure progression during pressure overload stress.

Area of Science:

  • Cardiovascular Physiology
  • Metabolic Adaptation
  • Heart Failure Pathophysiology

Background:

  • Pressure overload hypertrophy (POH) involves increased cardiac glucose utilization.
  • The role of endogenous glucose transporter type 1 (GLUT1) in this adaptation is unclear.

Purpose of the Study:

  • To determine if GLUT1 induction is necessary for maintaining cardiac function during hemodynamic stress.
  • To test if GLUT1 deficiency accelerates heart failure progression under POH.

Main Methods:

  • Mice with cardiomyocyte-specific GLUT1 deletion (G1KO) and controls underwent transverse aortic constriction (TAC).
  • Assessed cardiac function, hypertrophy, fibrosis, capillary density, and substrate utilization (glycolysis, fatty acid oxidation).

Main Results:

  • GLUT1 deficiency reduced glucose oxidation and glycolysis, increasing fatty acid oxidation.
  • TAC induced cardiac hypertrophy, fibrosis, and capillary loss similarly in G1KO and controls.
  • G1KO hearts showed reduced developed pressure post-TAC, but contractile dysfunction and mitochondrial impairment were equivalent to controls.

Conclusions:

  • GLUT1 deficiency alters myocardial substrate utilization but does not exacerbate pressure overload-induced contractile dysfunction.
  • Lack of endogenous GLUT1 does not accelerate the transition to heart failure in this model.

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.9K
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
805
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.8K
Cellular Adaptation II: Hypertrophy01:26

Cellular Adaptation II: Hypertrophy

Hypertrophy is the increase in the size of individual cells, resulting in the enlargement of a tissue or organ. Unlike hyperplasia, which involves an increase in cell number, hypertrophy is characterized by an increase in cell volume. This process often occurs in response to higher functional demand or hormonal stimulation, leading to the production of more structural proteins and organelles, thereby enhancing the cells' work capacity.There are two primary types of hypertrophy:...
54
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
790
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
753